首页> 美国卫生研究院文献>Annals of Oncology >Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives
【2h】

Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives

机译:乳腺癌和中枢神经系统转移患者的发展性疗法:当前的前景和未来的前景

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Breast cancer is the second-leading cause of metastatic disease in the central nervous system (CNS). Recent advances in the biological understanding of breast cancer have facilitated an unprecedented increase of survival in a subset of patients presenting with metastatic breast cancer. Patients with HER2 positive (HER2+) or triple negative breast cancer are at highest risk of developing CNS metastasis, and typically experience a poor prognosis despite treatment with local and systemic therapies. Among the obstacles ahead in the realm of developmental therapeutics for breast cancer CNS metastasis is the improvement of our knowledge on its biological nuances and on the interaction of the blood–brain barrier with new compounds. This article reviews recent discoveries related to the underlying biology of breast cancer brain metastases, clinical progress to date and suggests rational approaches for investigational therapies.
机译:乳腺癌是中枢神经系统(CNS)转移性疾病的第二大诱因。对乳腺癌的生物学了解的最新进展促进了一部分转移性乳腺癌患者的生存率空前提高。患有HER2阳性(HER2 +)或三阴性乳腺癌的患者发生中枢神经系统转移的风险最高,尽管进行了局部和全身治疗,但预后通常较差。乳腺癌中枢神经系统转移治疗的发展疗法领域中的障碍之一是,我们对它的生物学差异以及血脑屏障与新化合物相互作用的认识的提高。本文回顾了与乳腺癌脑转移的潜在生物学相关的最新发现,迄今为止的临床进展,并提出了用于研究治疗的合理方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号